Nerve growth factor (NGF) gene therapy rescues and stimulates cholinergic neurons, which degenerate in Alzheimer's disease (AD). In a recent clinical trial for AD, intraparenchymal adeno-associated virus serotype 2 (AAV2)-NGF delivery was safe but did not improve cognition. Before concluding that NGF gene therapy is ineffective, it must be shown that AAV2-NGF successfully engaged the target cholinergic neurons of the basal forebrain. In this study, patients with clinically diagnosed early- to middle-stage AD received a total dose of 2 × 1011 vector genomes of AAV2-NGF by stereotactic injection of the nucleus basalis of Meynert. After a mean survival of 4.0 years, AAV2-NGF targeting, spread, and expression were assessed by immunolabeling of NGF and the low-affinity NGF receptor p75 at 15 delivery sites in 3 autopsied patients. NGF gene expression persisted for at least 7 years at sites of AAV2-NGF injection. However, the mean distance of AAV2-NGF spread was only 0.96 ± 0.34 mm. NGF did not directly reach cholinergic neurons at any of the 15 injection sites due to limited spread and inaccurate stereotactic targeting. Because AAV2-NGF did not directly engage the target cholinergic neurons, we cannot conclude that growth factor gene therapy is ineffective for AD. Upcoming clinical trials for AD will utilize real-time magnetic resonance imaging guidance and convection-enhanced delivery to improve the targeting and spread of growth factor gene delivery.
Get full access to this article
View all access options for this article.
References
1.
WhitehousePJ, PriceDL, StrubleRG, et al.Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982; 215:1237–1239.
2.
SchmitzTW, Nathan SprengR; Alzheimer's Disease Neuroimaging Initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun, 2016; 7:13249.
3.
MobleyWC, RutkowskiJL, TennekoonGI, et al.Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons. Brain Res, 1986; 387:53–62.
4.
HoltzmanDM, LiY, ParadaLF, et al.p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron, 1992; 9:465–478.
5.
LiY, HoltzmanDM, KromerLF, et al.Regulation of TrkA and ChAT expression in developing rat basal forebrain: evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci, 1995; 15:2888–2905.
6.
HeftiF. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci, 1986; 6:2155–2162.
RosenbergMB, FriedmannT, RobertsonRC, et al.Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science, 1988; 242:1575–1578.
9.
TuszynskiMH, U HS, AmaralDG, et al.Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci, 1990; 10:3604–3614.
10.
KoliatsosVE, NautaHJ, ClatterbuckRE, et al.Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey. J Neurosci, 1990; 10:3801–3813.
11.
KordowerJH, WinnSR, LiuYT, et al.The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci U S A, 1994; 91:10898–10902.
12.
TuszynskiMH, RobertsJ, SenutMC, et al.Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Ther, 1996; 3:305–314.
13.
FischerW, WictorinK, BjörklundA, et al.Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature, 1987; 329:65–68.
14.
BishopKM, HoferEK, MehtaA, et al.Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol, 2008; 211:574–584.
15.
NagaharaAH, BernotT, MoseankoR, et al.Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol, 2009; 215:153–159.
16.
TuszynskiMH, ThalL, PayM, et al.A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med, 2005; 11:551–555.
17.
BankiewiczKS, EberlingJL, KohutnickaM, et al.Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol, 2000; 164:2–14.
18.
DuringMJ, KaplittMG, SternMB, et al.Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther, 2001; 12:1589–1591.
19.
JansonC, McPheeS, BilaniukL, et al.Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther, 2002; 13:1391–1412.
20.
CrystalRG, SondhiD, HackettNR, et al.Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther, 2004; 15:1131–1154.
21.
EberlingJL, JagustWJ, ChristineCW, et al.Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology, 2008; 70:1980–1983.
22.
RafiiMS, BaumannTL, BakayRAE, et al.A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement, 2014; 10:571–581.
23.
TuszynskiMH, YangJH, BarbaD, et al.Nerve growth factor gene therapy: activation of Neuronal Responses in Alzheimer Disease. JAMA Neurol, 2015; 72:1139–1147.
24.
RafiiMS, TuszynskiMH, ThomasRG, et al.Adeno-associated viral vector (serotype 2)—nerve growth factor for patients with Alzheimer disease. JAMA Neurol, 2018; 75:834–841.
25.
ConnerJM, MuirD, VaronS, et al.The localization of nerve growth factor-like immunoreactivity in the adult rat basal forebrain and hippocampal formation. J Comp Neurol, 1992; 319:454–462.
26.
SchindelinJ, Arganda-CarrerasI, FriseE, et al.Fiji: an open-source platform for biological-image analysis. Nat Methods, 2012; 9:676–682.
27.
RuedenCT, SchindelinJ, HinerMC, et al.ImageJ2: imageJ for the next generation of scientific image data. BMC Bioinformatics, 2017; 18:529.
28.
MontineTJ, PhelpsCH, BeachTG, et al.National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol, 2012; 123:1–11.
29.
HadaczekP, KohutnickaM, KrauzeMT, et al.Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther, 2006; 17:291–302.
30.
BoboRH, LaskeDW, AkbasakA, et al.Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A, 1994; 91:2076–2080.
31.
CunninghamJ, OiwaY, NagyD, et al.Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant, 2000; 9:585–594.
32.
SanftnerLM, SommerJM, SuzukiBM, et al.AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol, 2005; 194:476–483.
33.
MarksWJ, BartusRT, SiffertJ, et al.Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol, 2010; 9:1164–1172.
HuynhMB, OuidjaMO, ChantepieS, et al.Glycosaminoglycans from Alzheimer's disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau. PLoS One, 2019; 14:e0209573.
36.
SummerfordC, SamulskiRJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 1998; 72:1438–1445.
37.
WuH-Y, HudryE, HashimotoT, et al.Amyloid beta (Aβ) induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin (CaN) activation. J Neurosci, 2010; 30:2636–2649.
RichardsonRM, KellsAP, RosenbluthKH, et al.Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther, 2011; 19:1048–1057.
40.
ClinicalTrials.gov. Safety study of AADC gene therapy (VY-AADC01) for Parkinson's disease. https://clinicaltrials.gov/ct2/show/NCT01973543 (last accessed February26, 2020).
41.
ChristineCW, BankiewiczKS, Van LaarAD, et al.Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol, 2019; 85:704–714.
42.
ClinicalTrials.gov. A single-stage, adaptive, open-label, dose escalation safety and efficacy study of AADC deficiency in pediatric patients. https://clinicaltrials.gov/ct2/show/NCT02852213 (last accessed February26, 2020).
43.
SuX, KellsAP, Aguilar SalegioEA, et al.Real-time MR imaging with gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther, 2010; 18:1490–1495.
44.
NagaharaAH, WilsonBR, IvasykI, et al.MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Ther, 2018; 25:104–114.
45.
SamaranchL, SalegioEA, San SebastianW, et al.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 2012; 23:382–389.
46.
GraySJ, Nagabhushan KalburgiS, McCownTJ, et al.Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther, 2013; 20:450–459.
47.
CastleMJ, ChengY, AsokanA, et al.Physical positioning markedly enhances brain transduction after intrathecal AAV9 infusion. Sci Adv, 2018; 4:eaau9859.
48.
RosenbergJB, KaplittMG, DeBP, et al.AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer's disease. Hum Gene Ther Clin Dev, 2018; 29:24–47.
49.
ClinicalTrials.gov. Gene therapy for APOE4 homozygote of Alzheimer's disease. https://clinicaltrials.gov/ct2/show/NCT03634007 (last accessed February26, 2020).
50.
NoroozianZ, XhimaK, HuangY, et al.MRI-guided focused ultrasound for targeted delivery of rAAV to the brain. In: CastleMJ, ed. Adeno-Associated Virus Vectors. Clifton, NJ: Humana Press, 2019:177–197.
51.
Weber-AdrianD, KofoedRH, ChanJWY, et al.Strategy to enhance transgene expression in proximity of amyloid plaques in a mouse model of Alzheimer's disease. Theranostics, 2019; 9:8127–8137.
52.
DevermanBE, PravdoPL, SimpsonBP, et al.Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol, 2016; 34:204–209.
53.
ChanKY, JangMJ, YooBB, et al.Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci, 2017; 20:1172–1179.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
